MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EKF.L stock logo

EKF.L

EKF Diagnostics Holdings plc

$24.5
-0.75
 (-2.97%)
Exchange:  LSE
Market Cap:  105.571M
Shares Outstanding:  457.001M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Gavin Joseph Jones
Full Time Employees:  303
Address: 
Avon House
Cardiff
CF64 2EZ
GB
Website:  https://www.ekfdiagnostics.com
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers’ milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue52,61150,19451,564
Gross Profit23,85921,48026,480
EBITDA7,67811,1586,746
Operating Income2,0816,4596,746
Net Income2,3526,2422,122

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets80,84981,74581,137
Total Liabilities12,6328,53310,862
Total Stockholders Equity67,11772,32769,050
Total Debt4,0991,3181,385
Cash and Cash Equivalents6,02014,30115,834

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow6,31113,6569,707
Capital Expenditure-6,975-2,246-1,530
Free Cash Flow-66411,4108,177
Net Income2,1316,2422,122
Net Change in Cash-3,8526,5751,533

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)65,251.402Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)65,663.580Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)65,400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)10,453.118Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)10,519.148Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)10,476.923Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)10,726.146Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)10,814.284Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)10,757.920Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)19,513.338Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)19,636.600Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)19,557.776Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.020Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.020Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.020Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
2.05
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
51.76
?Enterprise Value
 (TTM)
: 
91.146M  ?EV/FCF
 (TTM)
: 
11.15
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.03  ?ROIC
 (TTM)
: 
0.03
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.02
?P/B
 (TTM)
: 
1.59  ?Current Ratio
 (TTM)
: 
4.16

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
923.46Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EKF Intrinsic Value

Common questions about EKF.L valuation

Is EKF Diagnostics Holdings plc (EKF.L) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for EKF Diagnostics Holdings plc (EKF.L) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EKF.L a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EKF.L trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EKF.L’s P/E ratio?

You can see EKF.L’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EKF.L?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EKF.L a good long-term investment?

Whether EKF.L fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EKF.L

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.97
MARKETSnap

Trading Metrics:

Open: 24.5   Previous Close: 25.25
Day Low: 24.4   Day High: 25.59
Year Low: 19   Year High: 32
Price Avg 50: 25.05   Price Avg 200: 26.58
Volume: 111342   Average Volume: 428650

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for EKF

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read